Literature DB >> 28624994

Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

M Bartova1, J Hlavaty2, Y Tan3,4, C Singer5, K Pohlodek6, J Luha7, I Walter2.   

Abstract

Ezrin, radixin, moesin (ERM) are important membrane-cytoskeletal crosslinkers and are suggested to play important role in cancer progression and metastasis. Even though ERM proteins were generally considered to be functionally redundant and the most studied was ezrin, recent studies highlight their distinct roles in metastatic process. Little information is available regarding the role of individual ERM proteins and their phosphorylated forms in human breast cancer. Our study is the first to examine expression of ezrin, moesin and their phosphorylated forms in primary breast tumors and matched lymph node metastases (LNMs) and their correlation with clinicopathological variables. A total of 88 primary breast cancer, 91 LNMs, 54 intraductal carcinoma and 26 normal adjacent breast tissue samples from tissue microarrays were studied. Expression was determined by immunohistochemistry, the intensity and number of positive cells was scored. Statistical analysis of protein expression and patients' age, tumor grade and hormonal status was performed. No statistical significant difference was found in ezrin, moesin, p-ezrinTyr353 and pan-p-ezrinThr567/radixinThr564/moesinThr558 expression between primary tumors and LNMs. Even though it was not significant, moesin expression varied between primary tumors, intraductal carcinoma, normal breast adjacent tissue and LNMs. A significant positive correlation between moesin and tumor grade has been proven. Even though primary tumors and matched LNMs did not show different expression patterns, moesin correlated significantly with higher tumor grade. Its positivity in intraductal carcinoma and normal breast tissue adjacent to cancer might indicate its role in tumor intiation/progression.

Entities:  

Keywords:  Breast cancer metastasis; Ezrin; Moesin; Phosphorylation

Mesh:

Substances:

Year:  2017        PMID: 28624994     DOI: 10.1007/s10585-017-9853-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  59 in total

1.  Expression of ezrin in human embryonic, fetal, and normal adult tissues.

Authors:  Jian-Jun Xie; Fa-Ren Zhang; Li-Hua Tao; Zhuo Lü; Xiu-E Xu; Li-Yan Xu; En-Min Li
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

Review 2.  ErbB/EGF signaling and EMT in mammary development and breast cancer.

Authors:  Katharine M Hardy; Brian W Booth; Mary J C Hendrix; David S Salomon; Luigi Strizzi
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-04-06       Impact factor: 2.673

Review 3.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

4.  Ezrin and moesin expression in canine and feline osteosarcoma.

Authors:  Juraj Hlavaty; Birgitt Wolfesberger; Marlene Hauck; Barbara Obermayer-Pietsch; Andrea Fuchs-Baumgartinger; Ingrid Miller; Ingrid Walter
Journal:  Histol Histopathol       Date:  2016-11-30       Impact factor: 2.303

5.  Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma.

Authors:  Hiroichi Kobayashi; Junji Sagara; Hiroshi Kurita; Masayo Morifuji; Masamichi Ohishi; Kenji Kurashina; Shun'ichiro Taniguchi
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

6.  Dephosphorylation of ezrin as an early event in renal microvillar breakdown and anoxic injury.

Authors:  J Chen; J A Cohn; L J Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

7.  Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion.

Authors:  Ana Estecha; Lorena Sánchez-Martín; Amaya Puig-Kröger; Rubén A Bartolomé; Joaquín Teixidó; Rafael Samaniego; Paloma Sánchez-Mateos
Journal:  J Cell Sci       Date:  2009-09-01       Impact factor: 5.285

8.  Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer.

Authors:  Zhaojin Yu; Mingli Sun; Feng Jin; Qinghuan Xiao; Miao He; Huizhe Wu; Jie Ren; Lin Zhao; Haishan Zhao; Weifan Yao; Fengping Shan; Yaming Cao; Minjie Wei
Journal:  Oncol Rep       Date:  2015-05-08       Impact factor: 3.906

9.  Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation.

Authors:  Philippe Pujuguet; Laurence Del Maestro; Alexis Gautreau; Daniel Louvard; Monique Arpin
Journal:  Mol Biol Cell       Date:  2003-02-06       Impact factor: 4.138

10.  Talin regulates moesin-NHE-1 recruitment to invadopodia and promotes mammary tumor metastasis.

Authors:  Brian T Beaty; Yarong Wang; Jose Javier Bravo-Cordero; Ved P Sharma; Veronika Miskolci; Louis Hodgson; John Condeelis
Journal:  J Cell Biol       Date:  2014-06-02       Impact factor: 10.539

View more
  5 in total

1.  Could Moesin Be a New Marker for Indicating Progression in Endometrial Cancer?

Authors:  Elif Agacayak; Aysenur Keles; Ugur Deger; Mehmet Sirin Ozcelik; Nurullah Peker; Reyhan Gunduz; Murat Akkus; Huseyin Buyukbayram
Journal:  Cancer Manag Res       Date:  2022-03-24       Impact factor: 3.989

2.  S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells.

Authors:  Kyoko Kikuchi; Keely May McNamara; Yasuhiro Miki; Erina Iwabuchi; Ayako Kanai; Minoru Miyashita; Takanori Ishida; Hironobu Sasano
Journal:  Cell Oncol (Dordr)       Date:  2018-09-22       Impact factor: 7.051

3.  Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer.

Authors:  Ana E Zacapala-Gómez; Napoleón Navarro-Tito; Luz Del C Alarcón-Romero; Carlos Ortuño-Pineda; Berenice Illades-Aguiar; Eduardo Castañeda-Saucedo; Julio Ortiz-Ortiz; Olga L Garibay-Cerdenares; Marco A Jiménez-López; Miguel A Mendoza-Catalán
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

4.  Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.

Authors:  Ping Wang; Viktor Magdolen; Christof Seidl; Julia Dorn; Enken Drecoll; Matthias Kotzsch; Feng Yang; Manfred Schmitt; Oliver Schilling; Anja Rockstroh; Judith Ann Clements; Daniela Loessner
Journal:  Br J Cancer       Date:  2018-10-05       Impact factor: 7.640

5.  Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation.

Authors:  Chunji Quan; Jie Sun; Zhenhua Lin; Tiefeng Jin; Bing Dong; Ziqi Meng; Junjie Piao
Journal:  Cancer Manag Res       Date:  2019-07-12       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.